이엔셀

456070KOSDAQ

50.8 / 100

Reference Date: 2026-09-08

Financial Score11.5 / 40

News Sentiment21.3 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 10.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

InCell operates two business models based on its GMP technology for cell and gene therapy drug development: CDMO (Contract Development and Manufacturing Organization) for advanced biopharmaceuticals and the development of next-generation cell and gene therapy drugs. The company holds the only GMP facility in South Korea capable of simultaneous cell and virus production, focusing on therapies for rare diseases like Charcot-Marie-Tooth and Duchenne muscular dystrophy.

Number of Employees

112people

Average Salary

42.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.55Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

-36.79Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

53.53Industry Average 100.005.0Point

Lower than industry avg (good)

Trend 2024~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼27.1% (1-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼14.2% (1-year basis)

ROE Trend

0.0 / 4

Avg ROE -36.0% (declining, 2yr)

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 85

Positive
이엔셀, CAR-T 세포 수율 4배 높인 공정기술 특허 출원에 3%↑[...
이엔셀의 CAR-T 세포 수율 향상 기술 특허 출원으로 주가가 상승했다.
Positive
이엔셀 최대주주, 삼성생명공익재단·원앤파트너스와 의결권 공동행사...
이엔셀의 최대주주와 주요주주 간 의결권 공동행사 연장으로 안정적인 지배구조 확보, 긍정적인 기업 운영 전망.
Positive
이엔셀, SVF 기반 항노화 재생의료 진출…스킨부스터 사업 추진
이엔셀이 SVF 기반 항노화 재생의료 및 스킨부스터 사업 진출로 신성장 동력 확보.

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 5,550Won52-week high 20,15052-week low 4,905

1-month return1.0Point

1m -10.05% (falling)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-08-27
Neutral주식등의대량보유상황보고서(일반)2026-08-24
Neutral반기보고서 (2026.06)2026-08-14